GlassScriptPhysician profile
Bradley A Connor
NPI 1366529620
$198,946.48
in general payments reported to CMS, 2019-2025
20 companies · $30K in 2025
The $30K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $49K · 2021: $29K · 2022: $40K · 2023: $8,103 · 2024: $10K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $28K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Travel and Lodging: $2,967 · Food and Beverage: $1,023.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $28,389.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,860.00 |
| Travel and Lodging | $2,967.32 |
| Food and Beverage | $1,022.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valneva USA, INC. | $135,179.34 | 2019-2025 | Ixiaro |
| Biomerieux INC | $31,673.80 | 2022-2025 | Filmarray Gastrointestinal (Gi) Panel, Biofire Filmarray Tropical Fever Panel, Filmarray Pneumonia Panel (Pneumo) |
| Redhill Biopharma INC. | $9,665.00 | 2020-2021 | |
| Biofire Diagnostics, LLC | $9,449.00 | 2019-2023 | Biofire Respiratory Panel 2.1 |
| Emergent Biosolutions INC. | $5,200.00 | 2021 | |
| Mayne Pharma Commercial LLC | $5,125.00 | 2021 | |
| Glaxosmithkline, LLC. | $1,800.00 | 2020 | |
| Phathom Pharmaceuticals, INC. | $277.63 | 2024 | Voquezna |
| Qol Medical, LLC | $146.50 | 2023 | Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.38 | 2019-2025 | Xifaxan |
| Boston Scientific Corporation | $78.62 | 2019-2023 | |
| Lupin INC. | $64.28 | 2019 | |
| Pfizer INC. | $55.70 | 2025 | |
| Ironwood Pharmaceuticals, INC | $25.64 | 2024 | |
| Aimmune Therapeutics, INC. | $23.24 | 2025 | Vowst |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $22.01 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $17.26 | 2022 | |
| Fujifilm Healthcare Americas Corporation | $15.37 | 2021 | |
| Lilly USA, LLC | $11.71 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Connor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.